Inmaculada Hernandez1, Yuting Zhang2, Maria M Brooks1, Paul K L Chin1, Samir Saba1. 1. From the Department of Pharmacy and Therapeutics, School of Pharmacy (I.H.), Department of Health Policy and Management, Graduate School of Public Health (Y.Z.), and Department of Epidemiology, Graduate School of Public Health (M.M.B.), University of Pittsburgh, PA; Department of Medicine, University of Otago, Christchurch, New Zealand (P.K.L.C.); and Heart and Valvular Institute, University of Pittsburgh Medical Centre, PA (S.S.). 2. From the Department of Pharmacy and Therapeutics, School of Pharmacy (I.H.), Department of Health Policy and Management, Graduate School of Public Health (Y.Z.), and Department of Epidemiology, Graduate School of Public Health (M.M.B.), University of Pittsburgh, PA; Department of Medicine, University of Otago, Christchurch, New Zealand (P.K.L.C.); and Heart and Valvular Institute, University of Pittsburgh Medical Centre, PA (S.S.). ytzhang@pitt.edu.
Abstract
BACKGROUND AND PURPOSE: Little is known about the clinical outcomes associated with posthemorrhage anticoagulation resumption for atrial fibrillation. This study had 2 objectives: first, to evaluate anticoagulation use after a first major bleed on warfarin or dabigatran and, second, to compare effectiveness and safety outcomes between patients discontinuing anticoagulation after a major bleed and patients restarting warfarin or dabigatran. METHODS: Using 2010 to 2012 Medicare Part D data, we identified atrial fibrillation patients who experienced a major bleeding event while using warfarin (n=1135) or dabigatran (n=404) and categorized them by their posthemorrhage use of anticoagulation. We followed them until an ischemic stroke, recurrent hemorrhage, or death through December 31, 2012. We constructed logistic regression models to evaluate factors affecting anticoagulation resumption and Cox proportional hazard models to compare the combined risk of ischemic stroke and all-cause mortality and the risk of recurrent bleeding between treatment groups. RESULTS: Resumption of anticoagulation with warfarin (hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.59-0.97) or dabigatran (HR 0.66; 95% CI 0.44-0.99) was associated with lower combined risk of ischemic stroke and all-cause mortality than anticoagulation discontinuation. The incidence of recurrent major bleeding was higher for patients prescribed warfarin after the event than for those prescribed dabigatran (HR 2.31; 95% CI 1.19-4.76) or whose anticoagulation ceased (HR 1.56; 95% CI 1.10-2.22), but did not differ between patients restarting dabigatran and those discontinuing anticoagulation (HR 0.65; 95% CI 0.32-1.33). CONCLUSIONS: Dabigatran was associated with a superior benefit/risk ratio than warfarin and anticoagulation discontinuation in the treatment of atrial fibrillation patients who have survived a major bleed.
BACKGROUND AND PURPOSE: Little is known about the clinical outcomes associated with posthemorrhage anticoagulation resumption for atrial fibrillation. This study had 2 objectives: first, to evaluate anticoagulation use after a first major bleed on warfarin or dabigatran and, second, to compare effectiveness and safety outcomes between patients discontinuing anticoagulation after a major bleed and patients restarting warfarin or dabigatran. METHODS: Using 2010 to 2012 Medicare Part D data, we identified atrial fibrillationpatients who experienced a major bleeding event while using warfarin (n=1135) or dabigatran (n=404) and categorized them by their posthemorrhage use of anticoagulation. We followed them until an ischemic stroke, recurrent hemorrhage, or death through December 31, 2012. We constructed logistic regression models to evaluate factors affecting anticoagulation resumption and Cox proportional hazard models to compare the combined risk of ischemic stroke and all-cause mortality and the risk of recurrent bleeding between treatment groups. RESULTS: Resumption of anticoagulation with warfarin (hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.59-0.97) or dabigatran (HR 0.66; 95% CI 0.44-0.99) was associated with lower combined risk of ischemic stroke and all-cause mortality than anticoagulation discontinuation. The incidence of recurrent major bleeding was higher for patients prescribed warfarin after the event than for those prescribed dabigatran (HR 2.31; 95% CI 1.19-4.76) or whose anticoagulation ceased (HR 1.56; 95% CI 1.10-2.22), but did not differ between patients restarting dabigatran and those discontinuing anticoagulation (HR 0.65; 95% CI 0.32-1.33). CONCLUSIONS:Dabigatran was associated with a superior benefit/risk ratio than warfarin and anticoagulation discontinuation in the treatment of atrial fibrillationpatients who have survived a major bleed.
Authors: Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip Journal: Chest Date: 2010-03-18 Impact factor: 9.410
Authors: Peter Brønnum Nielsen; Torben Bjerregaard Larsen; Flemming Skjøth; Anders Gorst-Rasmussen; Lars Hvilsted Rasmussen; Gregory Y H Lip Journal: Circulation Date: 2015-06-09 Impact factor: 29.690
Authors: Charles V Pollack; Paul A Reilly; Richard Bernstein; Robert Dubiel; John Eikelboom; Stephan Glund; Menno V Huisman; Elaine Hylek; Chak-Wah Kam; Pieter W Kamphuisen; Joerg Kreuzer; Jerrold H Levy; Frank Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Jeffrey I Weitz Journal: Thromb Haemost Date: 2015-05-28 Impact factor: 5.249
Authors: N Sengupta; J D Feuerstein; V R Patwardhan; E B Tapper; G A Ketwaroo; A M Thaker; D A Leffler Journal: Am J Gastroenterol Date: 2014-12-16 Impact factor: 10.864
Authors: Laila Staerk; Gregory Y H Lip; Jonas B Olesen; Emil L Fosbøl; Jannik L Pallisgaard; Anders N Bonde; Anna Gundlund; Tommi B Lindhardt; Morten L Hansen; Christian Torp-Pedersen; Gunnar H Gislason Journal: BMJ Date: 2015-11-16
Authors: Jochen A Sembill; Claudia Y Wieser; Maximilian I Sprügel; Stefan T Gerner; Antje Giede-Jeppe; Caroline Reindl; Ilker Y Eyüpoglu; Philip Hoelter; Hannes Lücking; Joji B Kuramatsu; Hagen B Huttner Journal: J Neurol Date: 2018-08-20 Impact factor: 4.849
Authors: Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt Journal: Blood Adv Date: 2018-11-27
Authors: Zien Zhou; Jie Yu; Cheryl Carcel; Candice Delcourt; Jiehui Shan; Richard I Lindley; Bruce Neal; Craig S Anderson; Maree L Hackett Journal: BMJ Open Date: 2018-05-14 Impact factor: 2.692
Authors: Joseph Jy Sung; Philip Wy Chiu; Francis K L Chan; James Yw Lau; Khean-Lee Goh; Lawrence Hy Ho; Hwoon-Young Jung; Jose D Sollano; Takuji Gotoda; Nageshwar Reddy; Rajvinder Singh; Kentaro Sugano; Kai-Chun Wu; Chun-Yin Wu; David J Bjorkman; Dennis M Jensen; Ernst J Kuipers; Angel Lanas Journal: Gut Date: 2018-04-24 Impact factor: 23.059